2023-05-16 04:11:46 ET
- Emmaus Life Sciences press release ( OTCQX:EMMA ): Q1 GAAP EPS of -$0.07.
- Revenue of $6.8M (+110.5% Y/Y) beats by $1.8M .
- On March 31, 2023, the company had cash and cash equivalents of $1.8 million, compared with $2.0 million on December 31, 2022.
- Based on the company's cash and cash equivalents, anticipated future revenues, current liabilities and expected operating expenses, the company's working capital is insufficient to meet its current liabilities and anticipated future working capital requirements without obtaining additional loans from related parties or debt or equity financing from third parties or curtailing certain operations or activities.
For further details see:
Emmaus Life Sciences GAAP EPS of -$0.07, revenue of $6.8M beats by $1.8M